Alector AL001-3 is a phase-3 study for individuals at risk for or with frontotemporal dementia due to mutations in the progranulin gene. This study will provide genetic testing for individuals with a family history who may be eligible to participate. The length of the trial ranges from 48 weeks to 96 depending on the treatment condition.
MAIN REQUIREMENTS: Age 18-85; known carriers of heterozygous loss-of-function progranulin gene (GRN) mutations.
Required Diagnosis||Diagnosis of FTD and known carriers of heterozygous loss-of-function progranulin gene (GRN) mutations|
|Age||18 - 85 (inclusive)|
|Length||6 wks (screening) + 48 wks (symptomatic) or 96 wks (pre-symptomatic) of treatment period + 8 wks (safety follow-up).|
|Lumbar Puncture||Optional (1 at screening and 2 during the treatment period)|
For More Information||